Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17560242 | 0.84 | POLB (0.44) | L3MBTL1NPC1TSHRPDE4DPDE4B | |
| SCHEMBL2232809 | 0.83 | CNR1 (0.41) | L3MBTL1NPC1TSHRPDE4DPDE4B | |
| SCHEMBL19329161 | 0.83 | POLB (0.42) | L3MBTL1NPC1TSHRPDE4DPDE4B | |
| SCHEMBL424839 | 0.81 | TUBB4A (0.47) | L3MBTL1NPC1TSHRPDE4DMAPK1 | |
| SCHEMBL424710 | 0.81 | L3MBTL1 (0.48) | L3MBTL1NPC1TSHRMAPK1MEN1 | |
| SCHEMBL2526740 | 0.71 | CNR1 (0.45) | MAPK1GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL22272883 | 0.71 | L3MBTL1 (0.40) | L3MBTL1PDE4DGAATDP1MEN1 | |
| SCHEMBL31172660 | 0.70 | PDE4D (0.42) | L3MBTL1TSHRPDE4DPDE4BGAA | |
| SCHEMBL10696793 | 0.70 | MERTK (0.58) | L3MBTL1NPC1TDP1MEN1KMT2A | |
| SCHEMBL17593199 | 0.69 | HPGD (0.42) | L3MBTL1PDE4DPDE4BGAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426350-B1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LTD (AU) | 2020-12-30 | — | — | EP | disclosed |
| US-10745380-B2 | Pyridine derivatives and their use in the treatment of cancer and hemoglobinopathies | CTXT PTY LTD (AU) | 2020-08-18 | — | — | US | disclosed |
| US-20200039956-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LTD (AU) | 2020-02-06 | — | — | US | disclosed |
| EP-3426350-A1 | PYRIDINE DERIVATIVES AND THIER USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | Ctxt Pty Ltd (AU) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017153521-A1 | PYRIDINE DERIVATIVES AND THIER USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039956-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | HBB, HBG2, HCCS | L3MBTL1 579/4885NPC1 2175/4885TSHR 1088/4885 |
| US-10745380-B2 | Pyridine derivatives and their use in the treatment of cancer and hemoglobinopathies | HBB, HBG2, HCCS | L3MBTL1 579/4885NPC1 2175/4885TSHR 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.